CD19 and lymphoma: GA further demonstrates synergy with adoptive cell therapy: in lymphoma models, it modulates the STAT3 pathway to enhance anti-CD19 CAR-T cell proliferation, reduce therapy-related toxicity, and prolong CAR-T persistence in tumors (131).